Journal of Hepatocellular Carcinoma

Scope & Guideline

Transforming research into impactful liver cancer therapies.

Introduction

Delve into the academic richness of Journal of Hepatocellular Carcinoma with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN-
PublisherDOVE MEDICAL PRESS LTD
Support Open AccessNo
Country-
Type-
Converge-
AbbreviationJ HEPATOCELL CARCINO / J. HEPATOCELL. CARCINOMA
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressPO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND

Aims and Scopes

The Journal of Hepatocellular Carcinoma focuses on advancing the understanding and treatment of hepatocellular carcinoma (HCC) through innovative research methodologies and interdisciplinary approaches.
  1. Clinical Research and Trials:
    The journal publishes studies that investigate various clinical aspects of hepatocellular carcinoma, including treatment efficacy, patient outcomes, and therapeutic strategies across different patient demographics.
  2. Molecular and Genetic Studies:
    Research contributions often explore the molecular mechanisms underlying HCC, including genetic mutations, epigenetic modifications, and their implications for prognosis and treatment.
  3. Imaging and Radiomics:
    The journal emphasizes the role of advanced imaging techniques and radiomic analysis in predicting HCC progression, microvascular invasion, and treatment response.
  4. Immunotherapy and Targeted Therapies:
    A significant focus is placed on the development and clinical application of immunotherapeutic approaches and targeted therapies, particularly in combination with traditional treatments like transarterial chemoembolization.
  5. Biomarkers and Prognostic Models:
    Research on identifying novel biomarkers for early detection, prognosis, and treatment response prediction is a core area, aimed at enhancing personalized medicine in HCC.
  6. Public Health and Disparities:
    The journal also addresses healthcare disparities and the impact of socioeconomic factors on HCC treatment outcomes, contributing to a broader understanding of the disease in diverse populations.
The Journal of Hepatocellular Carcinoma is witnessing a dynamic evolution in its research focus, with several emerging themes gaining traction in recent years.
  1. Artificial Intelligence and Machine Learning:
    Recent publications increasingly utilize AI and machine learning techniques for predictive modeling, enhancing diagnostic accuracy, and personalizing treatment strategies for HCC patients.
  2. Combination Therapy Strategies:
    There is a growing trend towards exploring combination therapies, particularly integrating immunotherapy with traditional treatments, reflecting the need for more effective and comprehensive treatment regimens.
  3. Metabolic and Nutritional Factors:
    Research examining the role of metabolic syndrome, nutrition, and specific metabolic pathways in HCC progression and treatment response is emerging as a significant area of interest.
  4. Patient-Centered Care and Quality of Life:
    Studies focused on patient-reported outcomes, quality of life, and healthcare disparities are becoming more prominent, indicating a shift towards a more holistic approach to HCC management.
  5. Novel Biomarker Discovery:
    There is an increased emphasis on identifying and validating novel biomarkers for early detection and monitoring treatment response, driven by advances in genomic and proteomic technologies.

Declining or Waning

While the Journal of Hepatocellular Carcinoma continues to cover a wide range of topics, certain themes appear to be losing prominence in recent publications.
  1. Traditional Chemotherapy Approaches:
    Research focusing on conventional chemotherapy methods has decreased as newer targeted therapies and immunotherapies gain traction, reflecting a shift in treatment paradigms.
  2. Single-Modality Treatments:
    The emphasis on single-modality treatments, such as isolated surgical resection or standalone chemoembolization, is waning in favor of multimodal approaches that combine various therapies for improved outcomes.
  3. Basic Science without Clinical Application:
    There is a noticeable decline in studies that focus solely on basic science or laboratory findings without direct clinical relevance or application, as the journal increasingly prioritizes translational research.
  4. Epidemiological Studies:
    The frequency of purely epidemiological studies examining HCC incidence and prevalence is decreasing, possibly as the journal shifts towards more intervention-focused research.

Similar Journals

Clinical and Molecular Hepatology

Bridging clinical practice and molecular discoveries in liver health.
Publisher: KOREAN ASSOC STUDY LIVERISSN: 2287-2728Frequency: 4 issues/year

Clinical and Molecular Hepatology, published by the Korean Association for the Study of Liver, stands at the forefront of hepatology, offering a significant platform for research and innovation in liver diseases. Established in 1995 as an open access journal, it aims to disseminate high-quality research that spans the fields of hepatology, molecular biology, and medicine. With an impressive impact factor ranking it in the Q1 category for 2023 in both Hepatology and Molecular Biology, the journal facilitates a rich exchange of knowledge among professionals, researchers, and students globally. With its dedicated coverage from 2012 to 2024 and exceptional Scopus rankings placing it within the top 10% of journals in its field, Clinical and Molecular Hepatology is an indispensable resource for advancing the understanding and treatment of liver conditions. Located in Seoul, South Korea, the journal emphasizes rigorous peer review and is committed to enhancing clinical practice and molecular research, making it an ideal venue for groundbreaking studies in liver health.

Clinical and Experimental Hepatology

Uncovering New Horizons in Hepatology
Publisher: TERMEDIA PUBLISHING HOUSE LTDISSN: 2392-1099Frequency: 4 issues/year

Clinical and Experimental Hepatology is a pivotal journal dedicated to advancing the field of hepatology, providing a platform for researchers, clinicians, and students to disseminate and explore groundbreaking findings. Published by TERMEDIA PUBLISHING HOUSE LTD in Poland, this journal serves as a vital resource for professionals seeking to enhance their knowledge and contributions in the realm of liver diseases and their management. With an impact factor reflective of its growing influence—ranking Q3 in Hepatology for the year 2023 and holding the 49th position out of 82 in Scopus Medicine Hepatology ranks—this publication underscores the significance of innovative research in this specialized domain. While it currently operates through a subscription model rather than open access, it bridges the gap in hepatological literature by featuring a diverse array of scholarly articles, case reports, and reviews from 2015 to 2024. Researchers and health professionals alike will find valuable insights that can enhance clinical practice and inform future studies, solidifying its importance in the hepatology community.

LIVER INTERNATIONAL

Advancing hepatology through cutting-edge research.
Publisher: WILEYISSN: 1478-3223Frequency: 12 issues/year

LIVER INTERNATIONAL, with its ISSN 1478-3223 and E-ISSN 1478-3231, is a prestigious peer-reviewed journal published by Wiley in the United Kingdom. Established in 2003, it focuses on advancing the field of hepatology, covering a broad spectrum of topics including liver disease, hepatocellular carcinoma, and transplantation. Ranking #10 out of 82 in the Scopus category for Medicine - Hepatology and boasting a remarkable 88th percentile, LIVER INTERNATIONAL has secured its reputation as a leading journal, recognized as Q1 in the 2023 category quartiles. The journal emphasizes accessibility, offering an open access option to ensure that critical research findings reach a wider audience. By facilitating the dissemination of high-quality research, LIVER INTERNATIONAL plays a vital role in shaping contemporary hepatological discourse and bridging academic inquiry with clinical practice, making it an essential resource for researchers, healthcare professionals, and students alike.

Hepatic Oncology

Elevating Research on Hepatic Malignancies
Publisher: FUTURE MEDICINE LTDISSN: 2045-0923Frequency: 4 issues/year

Hepatic Oncology is a premier Open Access journal published by Future Medicine Ltd that specializes in the critical intersection of hepatology and oncology. With a focus on advancing knowledge in the diagnosis and treatment of liver cancers, the journal provides a platform for innovative research, reviews, and clinical perspectives that serve as a valuable resource for researchers, clinicians, and students alike. Established in 2016 and evolving over the years, Hepatic Oncology underscores its commitment to accessible scientific communication, having transitioned to open access in 2018 to reach a broader audience. The journal holds a Q4 quartile ranking in the fields of hepatology and oncology for 2023, reflecting its emerging influence and role in contemporary research. Through high-quality articles and a focus on real-world applications, Hepatic Oncology aims to bridge gaps in knowledge while fostering collaboration among professionals dedicated to enhancing patient care in hepatic malignancies.

Hepatoma Research

Unveiling Insights in Hepatology and Oncology
Publisher: OAE PUBLISHING INCISSN: 2394-5079Frequency: 1 issue/year

Hepatoma Research is a pivotal academic journal dedicated to advancing the field of hepatology and oncology, published by OAE PUBLISHING INC. Launched in 2019, this open-access journal has quickly established itself as a valuable resource for researchers and professionals dedicated to the study of liver cancer and related disorders. With an ISSN of 2394-5079 and E-ISSN 2454-2520, it offers insightful research articles and reviews aimed at enhancing clinical practices and understanding the complexities surrounding hepatoma. The journal is ranked in the Q3 category for both hepatology and oncology as of 2023, reflecting its commitment to quality amidst a competitive landscape. With its Scopus rankings placing it at the 47th percentile in hepatology and the 39th percentile in oncology, Hepatoma Research continues to be a crucial platform for disseminating groundbreaking findings. This journal underscores the importance of collaborative research and encourages submissions that contribute to the global discourse on liver cancer treatment and management.

Clinical Genitourinary Cancer

Inspiring the future of genitourinary cancer care.
Publisher: CIG MEDIA GROUP, LPISSN: 1558-7673Frequency: 6 issues/year

Clinical Genitourinary Cancer, published by CIG MEDIA GROUP, LP, is a leading journal in the fields of Oncology and Urology, with an impressive impact reflected in its quartile rankings (Q2 in Oncology and Q1 in Urology for 2023) and strong Scopus rankings (22nd in Urology and 162nd in Oncology). The journal aims to innovate and inspire new research in genitourinary malignancies, providing a platform for the latest findings in diagnosis, treatment, and patient management. With its commitment to high-quality publications since its establishment in 2005, Clinical Genitourinary Cancer serves a crucial role in advancing the understanding of these complex conditions and enhancing clinical practices. Researchers, professionals, and students in the medical community are encouraged to engage with this essential resource, which facilitates open access to pioneering studies that drive the field forward.

Molecular Cancer

Connecting researchers to revolutionize cancer care.
Publisher: BMCISSN: Frequency: 1 issue/year

Molecular Cancer, published by BMC, stands as a premier open access journal dedicated to advancing our understanding of cancer biology, treatment, and prevention since its inception in 2002. With an impressive Q1 ranking in the domains of Cancer Research, Molecular Medicine, and Oncology, this journal occupies a significant position in the academic landscape, emphasizing high-quality research that influences clinical practices and future studies. The journal is indexed in leading databases with exceptional Scopus ranks, reflecting its rigorous peer-review process and impactful contributions to the field, where it ranks in the top 2-3 positions across various relevant categories. Based in the United Kingdom, Molecular Cancer offers researchers worldwide a valuable platform for disseminating innovative findings that drive the biomedical community forward. The journal's open access model ensures that groundbreaking research is freely accessible, fostering collaboration and knowledge sharing among professionals, students, and academics alike. Explore cutting-edge developments in cancer research through Molecular Cancer and join a community committed to improving patient outcomes and advancing scientific discovery.

CANCER RESEARCH

Elevating the standards of cancer research and innovation.
Publisher: AMER ASSOC CANCER RESEARCHISSN: 0008-5472Frequency: 24 issues/year

Cancer Research, published by the American Association for Cancer Research, is a premier journal in the field of oncology, renowned for its commitment to advancing cancer research since its inception in 1941. With an impressive impact factor reflecting its vital role in the field, this journal consistently ranks in the Q1 quartile for both Cancer Research and Oncology, positioning it among the top 7.5% of journals in these categories. The journal serves as a crucial platform for researchers, professionals, and students to disseminate and gain insights into groundbreaking studies that shape our understanding of cancer biology, prevention, diagnosis, and treatment. While it is not an open-access publication, its rigorous peer-review process ensures that only high-quality research is published, thus maintaining a standard of excellence in the scientific community. With a strong legacy and an ever-expanding influence, Cancer Research continues to be essential for anyone dedicated to the fight against cancer, showcasing cutting-edge research that drives scientific discovery and innovation.

JTO Clinical and Research Reports

Connecting Researchers and Clinicians for Impactful Discoveries
Publisher: ELSEVIERISSN: Frequency: 12 issues/year

JTO Clinical and Research Reports is an esteemed open-access journal published by Elsevier, dedicated to advancing knowledge in the fields of Oncology and Pulmonary and Respiratory Medicine. Since its inception in 2020, the journal has rapidly gained recognition, achieving a commendable Q1 ranking in both fields as of 2023, highlighting its significant contribution to high-quality research and clinical practice. With an inclusive global reach, JTO Clinical and Research Reports fosters collaboration by allowing unrestricted access to its content, ensuring that vital research findings can be disseminated widely among researchers, clinicians, and students alike. Located in the United States, and with its editorial base in the Netherlands, this journal not only embraces the mission of open science but also strives to publish impactful studies that address critical challenges in cancer treatment and respiratory health. Through its rigorous peer-review process and commitment to excellence, JTO Clinical and Research Reports aims to be at the forefront of scientific discourse and innovation in these dynamic areas of medicine.

HEPATOLOGY RESEARCH

Unveiling the complexities of liver health with cutting-edge research.
Publisher: WILEYISSN: 1386-6346Frequency: 12 issues/year

Hepatology Research, ISSN 1386-6346 and E-ISSN 1872-034X, is a premier academic journal published by Wiley that serves the dynamic fields of Hepatology and Infectious Diseases. With an impressive 2023 impact factor and ranked Q2 in Hepatology and Q1 in Infectious Diseases, this journal stands out as a vital resource for researchers, professionals, and students. Covering a broad spectrum of topics related to liver health, the journal aims to disseminate cutting-edge research and insights from the converged years of 1997 to 2024. As an open-access platform, it fosters the global sharing of knowledge, providing valuable access to pioneering studies that address pressing issues in liver disease and its associated infections. Based in the United Kingdom, at 111 River St, Hoboken, NJ, Hepatology Research is pivotal for advancing scientific understanding and improving patient outcomes worldwide.